Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Priya Jayachandran

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
Journal for Immunotherapy of Cancer|February 3, 2022
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancersGiovanni Fucà, Romain Cohen, Sara Lonardi, et al.
Journal for Immunotherapy of Cancer|January 11, 2024
<i>CCR5</i> and <i>CCL5</i> gene expression in colorectal cancer: comprehensive profiling and clinical valueFrancesca Battaglin, Yasmine Baca, Joshua Millstein, et al.
Oncogene|November 3, 2021
Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancerHiroyuki Arai, Andrew Elliott, Joshua Millstein, et al.
European Journal of Cancer (Oxford, England : 1990)|February 15, 2024
Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancerHiroyuki Arai, Yan Yang, Yasmine Baca, et al.
Journal for Immunotherapy of Cancer|February 10, 2025
Sex and outcomes of patients with microsatellite instability-high and <i>BRAF</i> V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitorsVincenzo Nasca, Joseph Zhao, Javier Ros, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
Journal for Immunotherapy of Cancer|February 3, 2022
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancersGiovanni Fucà, Romain Cohen, Sara Lonardi, et al.
Journal for Immunotherapy of Cancer|January 11, 2024
<i>CCR5</i> and <i>CCL5</i> gene expression in colorectal cancer: comprehensive profiling and clinical valueFrancesca Battaglin, Yasmine Baca, Joshua Millstein, et al.
Oncogene|November 3, 2021
Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancerHiroyuki Arai, Andrew Elliott, Joshua Millstein, et al.
European Journal of Cancer (Oxford, England : 1990)|February 15, 2024
Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancerHiroyuki Arai, Yan Yang, Yasmine Baca, et al.
Journal for Immunotherapy of Cancer|February 10, 2025
Sex and outcomes of patients with microsatellite instability-high and <i>BRAF</i> V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitorsVincenzo Nasca, Joseph Zhao, Javier Ros, et al.
Pageof 6